How do FDA shortage-list changes affect GLP-1 compounding insurance?

FDA shortage-list status is central to when and whether mass compounding of a GLP-1 drug is permitted, so changes to it directly affect a compounder's regulatory footing - and underwriters pay attention. When a drug is on the shortage list, compounding is generally more permissible; when it comes off, the permissibility narrows, and a compounder's activity that was acceptable can become a regulatory question.

For insurance, this shifting picture is part of why GLP-1 compounding is a high-scrutiny class. Carriers assess whether the operator's activity is on solid regulatory footing given the current shortage status, and a business model that depends on a drug remaining on the shortage list carries regulatory risk that underwriters weigh.

The practical point is that a GLP-1 compounder should be able to explain its regulatory basis clearly and demonstrate that its activity is compliant under the current status. Insurance does not cure a regulatory problem, but a well-documented, compliant operation is a materially better risk and easier to place.